Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting

BACKGROUND: HCV protease inhibitors (PIs) boceprevir and telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI therapy. Furtherm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Maasoumy, Benjamin, Port, Kerstin, Markova, Antoaneta Angelova, Serrano, Beatriz Calle, Rogalska-Taranta, Magdalena, Sollik, Lisa, Mix, Carola, Kirschner, Janina, Manns, Michael P., Wedemeyer, Heiner, Cornberg, Markus
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3562338/
https://ncbi.nlm.nih.gov/pubmed/23383319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0055285
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados